Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555615 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
NCT05555615 is a Phase 2 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 209 participants.
The verdict
NCT05555615, a Phase 2 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
Study Summary
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2025-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555615
The ClinicalTrials.gov registry entry for NCT05555615 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT05555615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05555615 about?
NCT05555615 is a clinical study titled "Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder". 52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-d...
What is the current status of trial NCT05555615?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2022-11-02. Estimated completion is 2025-02-14.
What interventions are being tested in trial NCT05555615?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT05555615?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.